Notice of Cipher Pharmaceuticals Inc. fiscal 2009 third quarter conference
call

    
    - Third quarter financial results to be released November 4, 2009 -

    Toronto Stock Exchange Symbol: DND
    

MISSISSAUGA, ON, Oct. 26 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), will host a conference call on Wednesday, November 4, 2009 at 8:30 a.m. (ET ) to discuss its fiscal 2009 third quarter financial results. Cipher invites all interested parties to participate. You can join the call by dialing 416-644-3419 or 1-800-814-4860. Please call in 15 minutes prior to the call to secure a line. You will be put on hold until the conference call begins.

Larry Andrews , President and CEO, will chair the call. A question and answer session will follow, at which time the operator will direct participants as to the correct procedure for submitting questions. A taped replay of the conference call will be available until Wednesday, November 11, 2009 by calling 416-640-1917 or 1-877-289-8525, reference number 4169809 followed by the number sign.

A live audio webcast of the conference call will be available through www.cipherpharma.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. An archived replay of the webcast will be available for 365 days.

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals is a drug development company focused on commercializing novel formulations of successful, currently marketed molecules using advanced drug delivery technologies. Cipher's strategy is to in-license products that incorporate proven drug delivery technologies and advance them through the clinical development and regulatory approval stages, after which the products are out-licensed to international partners. Because Cipher's products are based on proven technology platforms applied to currently marketed drugs, they are expected to have lower approval risk, shorter development timelines and significantly lower development costs. The Company's lead compound, CIP-FENOFIBRATE, received final approval from the U.S. Food and Drug Administration and Health Canada in the first quarter of 2006. The product is being marketed in the United States by Kowa Pharmaceuticals America under the label Lipofen(R). In addition, Cipher is developing formulations of the pain reliever tramadol (tentative FDA approval in February 2009 ) and the acne treatment isotretinoin (FDA approvable letter in April 2007).

Cipher is listed on the Toronto Stock Exchange under the symbol 'DND' and has approximately 24 million shares outstanding. For more information, please visit www.cipherpharma.com.

For further information: Craig Armitage, Investor Relations, The Equicom Group, [phone] ext 278, [phone] fax, [email protected]; Larry Andrews, President and CEO, Cipher Pharmaceuticals, [phone] ext 324, [phone] fax, [email protected]